The mechanisms of PD‐1/PD‐L1 inhibitor resistance include a lack of tumor immunogenicity, which results in the inability of T cells to recognize tumor cells, resistance of tumor cells to interferons, suppression of T‐cell responses by immunosuppressive factors myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells in the tumor microenvironment, and lack of T‐cell function.20 Here, CD274 is linked to neoplasm.